Liofora (Drospirenone, Ethinylestradiol)

Drospirenone acts as a progestogen with anti‑mineralocorticoid and anti‑androgenic properties, while ethinylestradiol is a synthetic estrogen. Together they bind to progesterone and estrogen receptors, suppressing the hypothalamic‑pituitary‑ovarian axis, which blocks the LH and FSH surge needed for ovulation and also thickens cervical mucus and alters the endometrium.

The dosing regimen for Liofora is determined by the prescribing healthcare professional. Typically, it involves taking one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions should be confirmed with the prescriber.

Liofora is contraindicated during pregnancy because it is intended to prevent conception. Women who become pregnant should discontinue the product. Limited data are available for breastfeeding; generally, combined oral contraceptives are considered compatible with lactation, but the prescriber should evaluate risks and benefits for each individual.

To order Liofora, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Liofora contains drospirenone, which offers anti‑mineralocorticoid and anti‑androgenic effects that may reduce water retention and improve acne compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, but individual tolerability and side‑effect profiles can differ, so clinicians choose based on patient needs.

Liofora tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep them in the original blister pack, protected from moisture, heat, and direct light. Do not store in the bathroom or near a kitchen sink, and keep out of reach of children.

Liofora is taken orally as a tablet. The usual practice is to swallow one tablet each day, preferably at the same time each day, with or without food. If a dose is missed, follow the prescriber’s instructions or the product’s patient information leaflet for appropriate action.

The most serious risks include venous thromboembolism (blood clots), arterial thrombosis (stroke or heart attack), and hypertension. These events are more likely in women who smoke, are over 35, have a history of clotting disorders, or have uncontrolled high blood pressure. Prompt medical attention is required if symptoms of clotting appear.

Liofora should not be used by women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or who are smokers over the age of 35. It is also contraindicated in patients with migraine with aura or known hypersensitivity to any component of the tablet.